Extended Data Fig. 3: Additional characterization of TRIM37 expression and synthetic lethality in breast cancer cell lines and patient-derived organoids (PDOs).
From: Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer
Related to Fig. 1. a, Immunoblot showing TRIM37 protein levels in the indicated 17q23-amplified cell lines (MDA-MB-361, BT474 and MCF-7) and non-17q23-amplified cell lines (BT549, MDA-MB-231 and MDA-MB-436) expressing control or TRIM37-targeting shRNA. β-Actin, loading control. Representative data; n = 3 biological replicates. For gel source data, see Supplementary Fig. 1. b, Clonogenic survival of 17q23-amplified and non-17q23-amplified cell lines treated with DMSO (control) or centrinone (PLK4i) (125 nM). Representative data; n = 3 biological replicates. c, Images of DMSO- or PLK4i-treated MDA-MB-361 and BT474 cells expressing control vector or TRIM37-targeting shRNA. Scale bars, 200 μm. Representative data; n = 3 biological replicates. d, Left, Representative flow cytometric DNA content analysis in DMSO- or PLK4i-treated MDA-MB-361 and BT474 cells. Percentages of sub-G1 events are indicated. Right, percentage of sub-G1 cells across n = 3 biological replicates. P values, unpaired two-tailed t-test. Mean ± s.e.m. e, TRIM37 gene expression in PDOs. Gene expression is reported as a z-score derived from RNA-seq data sets across n = 22 independent biological samples. f, Viability of patient-derived breast tumour organoids following a 14-d exposure to the indicated concentrations of centrinone. Data from n = 2 biological replicates are shown. Mean ± s.e.m. g, Immunoblot showing TRIM37 protein levels in PDOs. β-Actin, loading control. Data from n = 1 biological replicate. For gel source data, see Supplementary Fig. 1. h, Viability of 3D cultures of the indicated cell lines following a 14-d exposure to the indicated concentrations of centrinone. Left, n = 2 biological replicates, Mean ± s.e.m. Right, n = 4 technical replicates, Mean ± s.e.m.
